This PDF is the current document as it appeared on Public Inspection on 07/22/2015 at 08:45 am.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 30, 2015 (80 FR 37273). The document announced the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The document was published with an incorrect table title and contents. This document corrects those errors.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Lisa Granger, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.End Further Info End Preamble Start Supplemental Information
In FR Doc. 2015-16013, appearing in the Federal Register of Tuesday, June 30, 2015, the following corrections are made:
1. On page 37274, in the first column, the title of table 2, “Table 2. Revised Draft Product-Specific BE Recommendations for Drug Products Cholestyramine” is corrected to read “Table 2. Revised Draft Product-Specific BE Recommendations for Drug Products”.
2. On page 37274, in the first column, in the first line of the table under table 2, “Cholestyramine” is added to precede “Doxycycline hyclate, Prasugrel hydrochloride, Tiagabine hydrochloride”.Start Signature
Dated: July 17, 2015.
Associate Commissioner for Policy.
[FR Doc. 2015-18024 Filed 7-22-15; 8:45 am]
BILLING CODE 4164-01-P